GSK Is Maintained at Buy by Jefferies

GSK Is Maintained at Buy by Jefferies

Dow Jones02:09

Jefferies Maintains Buy on GSK, Raises Price Target to $53

Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.

Benzinga01:58

GSK Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 39.51% Jefferies $52.5 → $53 Maintains Buy 05/30/2024 23.72% Goldman Sachs → $47 Initiates Cove

Benzinga01:53

Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices

Seeking AlphaJul 2 21:17

Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims

A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer

BenzingaJul 2 20:39

Moderna Gets $176 Million From the U.S. to Make a Bird Flu Vaccine -- Barrons.com

By Josh Nathan-Kazis The drugmaker Moderna said Tuesday that it had received $176 million from the U.S. government to develop a messenger-RNA based bird flu vaccine for humans. The award, made throu

Barron'sJul 2 19:30